EUROQOL | ANBI
The Stichting EuroQol Research Foundation has been granted the status of Charitable Institution, in Dutch Algemeen Nut Beogende Instelling (ANBI), since January 1st, 2014. Shown below is information that an ANBI should make public. Please contact us if you have questions, or require more information.
| Name: | Stichting EuroQol Research Foundation |
| RSIN: | 804679101 |
| Address: | Marten Meesweg 107 3068 AV Rotterdam |
| Telephone: | +31 882026890 |
| Email: | EuroQol User Information Service |
| Board members: | See webpage Board |
Aims
Our Aims are in keeping with our Mission and Vision:
- To serve the public interest by supporting / instigating / performing scientific research and development of instruments which describe and value health without an aim for profit.
- To promote the scientific and other interests of the EuroQol Group Association (“EuroQol Group”).
- To manage intellectual property rights that the members of the EuroQol Group have acquired in the context of the EuroQol Group Association.
- To promote the use of instruments developed by the EuroQol Group and to support individuals and organizations across the world seeking to use those instruments.
- To foster and support an international community of researchers whose activity informs the development and application of EuroQol Group instruments.
- To ensure free access to the accumulated research expertise of the EuroQol Group and to actively promote the transfer of knowledge and evidence regarding the use, analysis, and interpretation of measures developed by the EuroQol Group.
- To support promising early career researchers in the field of health and quality of life research through involvement in EuroQol Group activities.
Policy Plan
For our policy plan please click here.
ANBI FORM
For the ANBI form, in Dutch only, see here.
Financial policy
- The Foundation does not have an aim for profit.
- The capital of the Foundation is formed by subsidies, gifts, bequests and other income. The Foundation receives financial support by means of sponsorship/ license income from commercial parties active in the development of drugs or medical devices. The Foundation requests a modest contribution to the costs of the development of the instruments when these are used in work that will not result in scientific publications in the public domain. No contribution is expected from EQ-5D use by non-commercial parties.
- In 2021 the Board of the Foundation approved the current investment policy. Please click here[insert URL] for the current version.
- The Foundation’s capital is used to finance scientific research studies and necessary software, an annual scientific congress and other scientific meetings and other costs of the Foundation, such as personnel costs.
- The members of the Board will not be remunerated for their activities.
- Personnel working for the Foundation are remunerated in line with the collective labour agreement aligned with Dutch Universities.
The Treasurer of the Board of the Foundation will present at least a balance sheet and the statement of income and expenses within 4 months after the financial year has ended on June 30th at the general assembly meeting of the EuroQol Group.
For the Balance sheet and the Statement of income and expenditure please see the Annual Report.
annual report
For the annual report please click here.
(Version18DEC2023)